PRISM BioLab Co

PRISM BioLab Co FCF/Debt

The Free Cash Flow to Debt Ratio of PRISM BioLab Co (206A.T) as of Nov 22, 2026 is -993.15 %. In the previous year, Free Cash Flow to Debt Ratio was -6.28 % — a change of 15,713.85% (lower).

FCF/Debt

-993.15 %

YoY

15,713.85%

Last updated:

Free Cash Flow to Debt Ratio of PRISM BioLab Co is 2025 -993.15 % . Free Cash Flow to Debt Ratio of PRISM BioLab Co was 2024 -6.28 % . It decreases by 15,713.85% lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PRISM BioLab Co Stock analysis

What does PRISM BioLab Co do? PRISM BioLab Co Ltd generates revenue through two distinct business models in the pharmaceuticals sector. The in-house development business focuses on selecting drug discovery targets and creating programs internally using their PepMetics technology platform. The joint development business collaborates with pharmaceutical companies to develop drug discovery programs leveraging their proprietary PepMetics technology. Both models utilize the company's owned drug discovery platform to create new pharmaceutical products. The company's primary clients are pharmaceutical companies seeking to develop new drugs through partnerships with PRISM BioLab's technology. PRISM BioLab's business model centers on its PepMetics technology, which serves as the foundation for both its in-house development and joint development segments. The company builds new drug discovery platforms and develops new drugs through these segments, targeting pharmaceutical companies as their main customers. The firm's research and development activities are conducted using their owned technology, which differentiates their approach in the drug discovery market. The company's revenue streams are derived from pharmaceutical companies that partner with PRISM BioLab for drug discovery programs. By utilizing their PepMetics technology platform, the company creates targeted drug discovery solutions that are developed either internally or in collaboration with pharmaceutical partners. This approach allows PRISM BioLab to generate income through both direct development efforts and collaborative projects with industry clients. PRISM BioLab Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PRISM BioLab Co stock

Free Cash Flow to Debt Ratio of PRISM BioLab Co is -993.15 % in 2025.

Free Cash Flow to Debt Ratio of PRISM BioLab Co changed from -6.28 % to -993.15 %, representing a 15,713.85% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio PRISM BioLab Co since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's PRISM BioLab Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — PRISM BioLab Co

All Key Metrics — PRISM BioLab Co